Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
76 hedge funds and large institutions have $1.27B invested in Soleno Therapeutics in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 12 closing their positions.
183% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 12
120% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 10
111% more capital invested
Capital invested by funds: $599M → $1.27B (+$668M)
41% more funds holding
Funds holding: 54 → 76 (+22)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
38% less call options, than puts
Call options by funds: $2.46M | Put options by funds: $3.98M
100.07% less ownership
Funds ownership: 203.22% → 103.15% (-100%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$148M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$70.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$22.3M |
| 5 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$36.6M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$33.7M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$9.59M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$8.43M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.34M |
SLNO Hedge Fund Activity: Q4 2023 in Review
76 of the 6,865 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2023, worth a combined $1.27B — up 111% from $599M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new SLNO positions and 12 closed out — a net gain of 22 holders — while 22 added to existing stakes and 10 trimmed.
The largest buyer was Vivo Capital, adding an estimated $148M. The largest seller was RA Capital Management, exiting entirely with an estimated $36.6M sold.
- 76 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2023, up from 54 in Q3 2023.
- Funds reported $1.27B of Soleno Therapeutics stock for Q4 2023, up 111% quarter-over-quarter.
- 34 funds opened new Soleno Therapeutics positions in Q4 2023 and 12 closed out, a net change of +22 holders.
- The largest Soleno Therapeutics buyer in Q4 2023 was Vivo Capital, an estimated $148M added.
- The largest Soleno Therapeutics seller in Q4 2023 was RA Capital Management, an estimated $36.6M sold.
Based on aggregated 13F filings for Q4 2023.